List view / Grid view

Yasunori Yamaguchi

Filter the results

 

news

Lonza and BioWa sign license agreements with Pfizer, Inc.

BioWa, Inc. and Lonza today announced that they have entered…

30 July 2013 | By

BioWa, Inc. and Lonza today announced that they have entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT® CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.

news

Lonza and Biowa sign license agreements with FivePrime Therapeutics

Five Prime Therapeutics, Inc. (“FivePrime”) has entered into research and…

13 June 2012 | By

Five Prime Therapeutics, Inc. (“FivePrime”) has entered into research and commercial agreements with BioWa, Inc. and Lonza to use their POTELLIGENT® CHOK1SV Cell Line for the research, development and production of multiple proprietary antibodies in FivePrime’s oncology pipeline.